Raphael Landovitz, MD, MSc

Dr. Landovitz received his BA in Chemistry from Princeton University (Princeton, New Jersey, USA), and received his medical degree from Harvard Medical School (Boston, Massachusetts, USA). Following this, he completed an internship, residency, and served as Chief Resident in Internal Medicine at Brigham and Women’s Hospital (Boston, Massachusetts, USA) and an Infectious Diseases fellowship with Brigham and Women’s Hospital and Massachusetts General Hospital (Boston, Massachusetts, USA). He then served as Medical Co-Director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment. He is an infectious disease and HIV clinician and clinical investigator whose research interests include HIV prevention (including pre- and post-exposure prophylaxis and other combination prevention strategies) and the impact of such prevention interventions on risk behavior. Dr. Landovitz works with the United States National Institutes of Health (NIH)-funded Division of AIDS (DAIDS) clinical trials networks for HIV therapeutics and HIV Prevention, and the network for COVID19 Prevention. He is has led numerous clinical trials, and currently leads the NIH trials developing long-acting injectable cabotegravir for HIV prevention. In 2010, he was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010, and the American Association of HIV Medicine Research Award in 2017. Dr. Landovitz is the Co-director of the UCLA Center for Clinical AIDS Research & Education (CARE) and of the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). During the COVID19 Pandemic, he has locally led COVID treatment and prevention clinical trials, and is the local principal investigator for the Astra Zeneca COVID 19 vaccine study, and he continues that work as a partner with Dr. Arleen Brown’s STOP COVID-19 CA initiative.